查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1988071

金诺芬市场：2026-2032年全球市场预测（依适应症、治疗领域、剂型、最终用户和通路划分）

Auranofin Market by Indication, Therapeutic Class, Dosage Strength, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，金诺芬市值将达到 2.3002 亿美元，到 2026 年将成长至 2.4773 亿美元，到 2032 年将达到 3.2296 亿美元，复合年增长率为 4.96%。

主要市场统计数据
基准年 2025 2.3002亿美元
预计年份：2026年 2.4773亿美元
预测年份 2032 3.2296亿美元
复合年增长率 (%) 4.96%

金诺芬在肿瘤学和类风湿性关节炎领域的重新定位表明，跨学科合作为改善治疗研发和疗效提供了机会。

金诺芬（Auranofin）作为一种具有悠久治疗历史的药物，因其不断扩展的临床信号通路和对药理学认识的加深而重新受到关注。金诺芬最初是为治疗风湿性疾病而研发和应用的，如今其作用机制因其潜在的抗癌和免疫调节作用而备受瞩目。这种重新评估促使包括临床研究人员、药物遴选委员会、製药公司和保险公司在内的众多相关人员重新审视金诺芬在现代治疗体系中的地位。

科学进步、监管变化和商业化趋势共同作用，重新定义了奥拉诺芬的临床定位和临床实验设计重点。

目前，金诺芬在科学、监管和商业性实施等多个领域正经历着变革性的变化。在科学方面，我们对氧化还原生物学、蛋白质稳态和免疫调节的理解不断深入，揭示了金诺芬可能发挥超出其预期适应症的有益作用的潜在机制。这些新发现，结合更先进的生物标记和转化模型，正在塑造现代临床项目和假设主导临床试验的设计。

预计美国将在 2025 年调整关税，这对金诺芬供应链的韧性、采购成本和临床试验营运产生影响。

2025年美国关税政策的变化将对包括奥拉诺芬在内的药品供应链产生影响。如果活性成分、包装材料或辅助材料来自海外，这种影响将特别显着。关税调整可能会改变製造商和合约伙伴的采购成本结构，促使他们重新评估供应商、修订合约并调整库存策略。这些因应措施通常与增强供应链韧性、降低单一来源依赖风险的努力同时进行。

对影响奥拉诺芬临床应用和市场定位的因素进行关键細項分析，按适应症、治疗领域、通路和剂量进行细分。

细分市场层面的趋势提供了关于如何在临床和营运环境中评估和实施奥拉诺芬的重要背景资讯。从适应症来看，重点产品组合集中在肿瘤和类风湿性关节炎。在肿瘤领域，重点是白血病和淋巴瘤患者群体，基于作用机制的证据和初步数据，这些患者群体可能从中获益。同时，在类风湿性关节炎领域，重点在于区分中度和重度疾病状态，以便调整对安全性监测和比较证据的预期。

美洲、欧洲、中东和非洲以及亚太地区的区域洞察：重点关注奥拉诺芬临床导入、监管细微差别和市场准入趋势的差异

区域差异影响着奥拉诺芬的临床应用、监管预期和供应策略。在美洲，临床开发往往由广泛的研究者主导的计画和紧密的学术机构网络推动，这使得假设能够快速检验，同时也要求与支付方的证据要求和医院采购的实际考虑高度契合。

从公司层面深入了解奥拉诺芬的研发重点、授权和合作活动、製造和供应方法以及差异化策略。

企业行动和策略定位对于奥拉诺芬计画从概念阶段到临床试验再到最终广泛应用的整个过程至关重要。不同机构的研发重点各不相同；有些机构优先考虑阐明药物作用机制和早期临床试验，而有些机构则专注于后期对比试验，以满足临床医生和支付方的循证需求。许可和合作通常被用作加速研发、扩大生产和分销能力的手段，而无需完全自主建构基础设施。

加强奥拉诺芬研发路径、保障供应链、改善试验设计、改善临床应用等的实用建议。

产业领导者应采取切实可行的优先措施，使科学预期与营运和市场准入的实际情况相符。首先，证据策略的製定应目标明确。申办者应儘早明确临床医师和支付者最关注的临床终点和真实世界终点，并设计能够产生与这些相关人员相关的比较数据和转化数据的临床试验。这有助于减少后续环节的阻力，并在结果积极的情况下促进快速应用于临床实践。

调查方法，结合有针对性的初步访谈、结构化的二次研究和严格的检验，以检验跨细分市场和地区的见解。

本研究途径整合了多方面的证据来源和检验步骤，以确保分析的严谨性和有效性。主要研究包括对临床医生、供应链专家、监管顾问和临床实验管理人员进行有针对性的保密访谈，以收集关于临床假设、营运限制和证据需求的第一手观点。这些访谈旨在识别不同适应症、治疗领域和最终使用环境中的实际障碍和潜在的缓解策略。

我们将负责任地推广奥拉诺芬，并将临床进展、政策和供应风险、细分市场机会以及相关人员的行为纳入我们的结论中。

现有证据表明，金诺芬有望成为重新定位的候选药物，其作用日益凸显，这需要临床、监管和营运等多个领域的协调努力。在临床方面，金诺芬在肿瘤和类风湿性关节炎领域的应用凸显了其广泛的潜在适用性，以及製定针对特定适应症的证据策略的必要性。在营运方面，分销管道和终端用户环境的差异表明，製剂、包装和支援服务对药物的实际应用效果有显着影响。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：奥拉诺芬市场：依适应症划分

  • 肿瘤学
    • 白血病
    • 淋巴瘤
  • 类风湿性关节炎
    • 缓和
    • 严重

第九章：依治疗分类分類的奥拉诺芬市场

  • DMARD
    • 生物製药
    • 传统的
    • 标靶定向药物
  • 黄金製剂

第十章：以剂量强度分類的奥拉诺芬市场

  • 3mg
  • 6mg

第十一章 金诺芬市场：以最终用户划分

  • 居家照护设施
  • 医院
  • 专科诊所

第十二章 金诺芬市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十三章 金诺芬市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 金诺芬市场：依集团划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 金诺芬市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国奥拉诺芬市场

第十七章：中国奥拉诺芬市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AGC Inc.
  • Ardagh Group SA
  • Corning Incorporated
  • Guardian Industries
  • Nippon Electric Glass Co. Ltd.
  • Owens-Illinois Inc.
  • Pilkington Group Limited
  • PPG Industries Inc.
  • Saint-Gobain SA
  • Schott AG
  • Vitro SAB de CV
Product Code: MRR-F97DD5A7D98B

The Auranofin Market was valued at USD 230.02 million in 2025 and is projected to grow to USD 247.73 million in 2026, with a CAGR of 4.96%, reaching USD 322.96 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 230.02 million
Estimated Year [2026] USD 247.73 million
Forecast Year [2032] USD 322.96 million
CAGR (%) 4.96%

Auranofin repositioning across oncology and rheumatoid arthritis signaling cross-disciplinary opportunities to enhance therapeutic development and outcomes

Auranofin has emerged from a longstanding therapeutic history with renewed interest driven by expanding clinical signals and a clearer understanding of its pharmacology. Initially developed and deployed in the context of rheumatologic indications, its mechanisms of action have attracted attention for potential anticancer and immunomodulatory uses. This repositioning has prompted a wide array of stakeholders-clinical investigators, formulary committees, manufacturers, and payers-to reassess where auranofin fits within contemporary treatment frameworks.

As clinical programs evolve, the drug's profile is being examined in parallel pathways: continued relevance in immune-mediated disease and growing exploration within oncology. This dual trajectory has introduced novel considerations around dosing strategies, safety monitoring, and comparative positioning relative to alternative therapeutic classes. At the same time, changes in regulatory expectations and payer scrutiny are influencing development strategies and evidence generation plans.

Taken together, these dynamics create both opportunity and complexity. Organizations engaging with auranofin must balance the demand for robust clinical validation with practical imperatives such as reliable supply, appropriate distribution arrangements, and clear value communication for clinicians and patients. The introduction establishes why auranofin's renewed relevance warrants careful strategic planning across clinical, operational, and access-related domains.

Scientific advances, regulatory shifts, and commercialization trends converging to redefine auranofin's clinical positioning and trial design priorities

The landscape for auranofin is undergoing several transformative shifts that span science, regulation, and commercial execution. On the scientific front, advances in understanding redox biology, protein homeostasis, and immune modulation have clarified plausible mechanisms through which auranofin could exert benefit beyond its original indication. These mechanistic insights have coincided with more sophisticated biomarkers and translational models, which together are shaping the design of contemporary clinical programs and hypothesis-driven trials.

Regulatory pathways have also recalibrated in ways that matter for repositioned drugs. Agencies increasingly encourage adaptive trial designs and real-world evidence integration when safety profiles are well-characterized, creating both pathways and expectations for sponsors. At the same time, heightened attention to benefit-risk balance and cost-effectiveness means that evidentiary strategies must be tightly aligned to payer and clinician needs from an earlier stage.

Commercially, shifts in distribution logistics, sourcing strategies, and manufacturer partnerships are influencing how developers think about scale-up and access. Strategic alliances-ranging from licensing agreements to contract manufacturing relationships-provide routes to secure supply, while collaborative research models enable more rapid validation of new indications. Together, these scientific, regulatory, and commercial inflections are redefining how stakeholders prioritize investments and allocate resources in support of auranofin's next-generation programs.

Anticipated United States tariff adjustments in 2025 and their effects on auranofin supply chain resilience, procurement costs, and clinical trial operations

Changes to tariff policy in the United States in 2025 have implications for pharmaceutical supply chains that extend to drugs like auranofin, particularly where active pharmaceutical ingredients, packaging, or secondary components are sourced internationally. Tariff adjustments can alter procurement economics for manufacturers and contract partners, prompting reassessments of sourcing locations, supplier contracts, and inventory strategies. These operational responses often happen alongside efforts to shore up resilience and reduce exposure to single-source dependencies.

Clinical research operations are also affected by shifts in import/export costs. Increased tariffs on raw materials or finished goods can influence trial budgets and logistics, especially for multicenter studies that rely on centralized supply distribution. Sponsors may need to modify shipment schedules, identify alternative vendors, or engage additional contingency planning to preserve trial timelines and data integrity. Importantly, procurement tactics that emphasize diversification and nearshoring can mitigate volatility but require lead time to implement.

Finally, payers and providers may experience downstream effects, as procurement cost pressures can influence formulary decisions and hospital purchasing agreements. Organizations considering expanded development or wider deployment of auranofin should therefore integrate tariff-related scenarios into supply planning, contract negotiations, and clinical operations so that contingency measures are in place to maintain continuity of care and research momentum.

Key segmentation insights revealing drivers of clinical application and positioning for auranofin across indications, therapy classes, channels, and dosages

Segment-level dynamics provide essential context for how auranofin is being evaluated and deployed in clinical and operational settings. When viewed by indication, the portfolio of interest clusters into oncology and rheumatoid arthritis; within oncology, focused efforts concentrate on leukemia and lymphoma populations where mechanistic rationale and preliminary data suggest potential benefit, while within rheumatoid arthritis attention differentiates between moderate and severe disease states to tailor safety monitoring and comparative evidence expectations.

Therapeutic class segmentation further clarifies positioning. Auranofin sits in the broader class of disease-modifying antirheumatic drugs and in the niche of gold compounds, prompting comparisons to biologics, conventional DMARDs, and targeted synthetic agents. These comparisons influence clinical trial endpoints and the kinds of head-to-head data that stakeholders often request, as well as the profile of real-world evidence that will support adoption in practice.

Distribution channel distinctions matter operationally and for patient access. Hospital pharmacies, online pharmacies, and retail pharmacies each have different procurement cycles, inventory management practices, and patient touchpoints, which in turn shape fulfillment strategies and clinician prescribing behavior. End-user segmentation-distinguishing home care settings from hospitals and specialty clinics-also drives packaging, dosing convenience, and support services that may be necessary for safe and effective use. Finally, dosage strength segmentation, typically between 3mg and 6mg formulations, underpins dosing algorithms, therapeutic monitoring plans, and comparative tolerability discussions. Integrating these layered segments enables stakeholders to make nuanced decisions about clinical evidence generation, supply arrangements, and adoption strategies that reflect real-world care pathways.

Regional insights across Americas, EMEA, and Asia-Pacific that highlight differences in clinical adoption, regulatory nuance, and access dynamics for auranofin

Regional variations shape clinical adoption, regulatory expectations, and supply strategies for auranofin. In the Americas, clinical development tends to be driven by extensive investigator-led programs and a dense network of academic centers, which supports rapid hypothesis testing but also requires strong alignment with payer evidence requirements and practical considerations for hospital procurement.

In Europe, Middle East & Africa, regulatory frameworks and reimbursement pathways vary markedly by country and region, creating a mosaic of evidence needs and access timelines. Stakeholders operating in this broader region must navigate heterogeneous HTA processes, diverse pricing dynamics, and distinct clinical practice patterns that influence how new or repurposed therapies are adopted.

Asia-Pacific exhibits its own set of drivers: rapid expansion of clinical trial capacity in several countries, strong manufacturing capabilities, and varied reimbursement environments. These factors create opportunities for regional manufacturing partnerships, accelerated enrollment for appropriately designed trials, and a need to calibrate evidence packages so they meet multiple regulatory and clinical expectations. Across all regions, local supply chain arrangements, distribution partners, and clinician education initiatives are critical to translating clinical evidence into practical availability for patients.

Company-level insights on R&D focus, licensing and partnership activity, manufacturing and supply approaches, and differentiation strategies around auranofin

Company behavior and strategic positioning are central to how auranofin programs progress from concept to clinic and to broader availability. Research and development focus varies across organizations, with some prioritizing mechanistic exploration and early-phase trials while others emphasize late-stage comparative studies that address clinician and payer evidence needs. Licensing and partnership activity frequently emerge as mechanisms to accelerate development or to expand manufacturing and distribution capabilities without the need for fully internalized infrastructure.

Manufacturing and supply strategies are another area of differentiation. Some companies invest in vertical integration to secure key active pharmaceutical ingredient flows, while others rely on contract manufacturing organizations and distributed supplier networks that can be reconfigured as demand evolves. Decisions about formulation, packaging, and dosage strengths influence not just clinical protocols but also production batch sizes, inventory strategies, and distribution suitability for hospital, retail, or home care settings.

Competitive differentiation often centers on the quality and specificity of the evidence base, the robustness of supply commitments, and the effectiveness of stakeholder engagement. Organizations that proactively align clinical programs with real-world needs, secure resilient supply arrangements, and cultivate collaborative relationships with clinical networks tend to preserve optionality and reduce implementation friction. These corporate-level choices define the trajectory of auranofin from investigational programs to practical therapeutic options.

Actionable recommendations to strengthen development pathways, secure supply chains, refine trial design, and improve clinical access for auranofin

Industry leaders should adopt pragmatic, prioritized actions to align scientific promise with operational and access realities. First, evidence strategies should be purpose-built: sponsors ought to define the clinical and real-world endpoints that matter most to clinicians and payers early, and design trials that generate comparative and translational data suited to those stakeholders. This reduces downstream friction and supports more rapid assimilation into clinical practice when results are positive.

Second, supply chain robustness must be elevated to a strategic priority. Organizations should map critical suppliers, assess single-source vulnerabilities, and develop alternative sourcing or nearshoring plans where appropriate. These steps enable continuity for both clinical programs and patient supply while tariffs and trade dynamics evolve.

Third, distribution and end-user needs must inform product and service design. Packaging, dosing regimens, and patient support services should be tailored to hospitals, specialty clinics, and home care settings to optimize adherence and safety. Finally, stakeholders should pursue collaborative approaches-whether through licensing, strategic partnerships, or investigator consortia-to share risk, access specialized capabilities, and accelerate evidence generation. Prioritizing these actions will improve the likelihood of responsible, scalable adoption and minimize operational disruptions.

Methodology combining targeted primary interviews, structured secondary research, and rigorous triangulation to validate insights across segments and regions

The research approach integrates multiple evidence streams and validation steps to ensure analytic rigor and relevance. Primary research included targeted, confidential interviews with clinicians, supply chain specialists, regulatory advisors, and trial operations leads to capture first-hand perspectives on clinical hypotheses, operational constraints, and evidence needs. These interviews were structured to surface practical barriers and potential mitigations across indications, therapeutic classes, and end-use settings.

Secondary research comprised a systematic review of peer-reviewed literature, regulatory guidance documents, clinical trial registries, and publicly available company disclosures to synthesize mechanistic understanding, safety data, and programmatic trends. Findings from primary and secondary sources were then subjected to triangulation: convergent themes were identified, divergent viewpoints were traced back to context, and key assertions were tested against multiple independent information points.

Throughout the process, attention was given to segment and regional specificity so that conclusions reflect the differences between clinical indications, therapeutic classes, distribution pathways, end users, and dosage strengths, as well as geographic distinctions. This layered methodology supports actionable insights that stakeholders can apply to clinical planning, supply decisions, and strategic partnerships.

Integrated conclusion synthesizing clinical momentum, policy and supply risks, segmentation opportunities, and stakeholder actions to responsibly advance auranofin

The evidence gathered points to auranofin's evolving role as a candidate for repositioning that demands coordinated attention across clinical, regulatory, and operational domains. Clinically, the dual focus on oncology and rheumatoid arthritis highlights both the breadth of potential applications and the need for indication-specific evidence strategies. Operationally, distribution channel distinctions and end-user settings underscore that formulation, packaging, and support services materially affect real-world usability.

Policy and supply considerations are equally consequential. Tariff dynamics, procurement practices, and manufacturing footprints will influence the feasibility of broad deployment and trial continuity. Responding to these factors requires proactive supply planning, flexible sourcing, and contractual safeguards that preserve access during periods of trade or logistic volatility.

Taken together, the most effective responses will be multidisciplinary: sponsors and manufacturers must coordinate trial design with operational logistics and payer engagement, while health systems should prepare clinical pathways that reflect differences in dosing, administration settings, and evidence thresholds. By centering strategy on validated clinical priorities, resilient supply arrangements, and clear stakeholder communication, organizations can responsibly advance auranofin programs and translate scientific potential into meaningful patient benefit.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Auranofin Market, by Indication

  • 8.1. Oncology
    • 8.1.1. Leukemia
    • 8.1.2. Lymphoma
  • 8.2. Rheumatoid Arthritis
    • 8.2.1. Moderate
    • 8.2.2. Severe

9. Auranofin Market, by Therapeutic Class

  • 9.1. DMARDS
    • 9.1.1. Biologics
    • 9.1.2. Conventional
    • 9.1.3. Targeted Synthetic
  • 9.2. Gold Compounds

10. Auranofin Market, by Dosage Strength

  • 10.1. 3mg
  • 10.2. 6mg

11. Auranofin Market, by End User

  • 11.1. Home Care Settings
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Auranofin Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Auranofin Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Auranofin Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Auranofin Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Auranofin Market

17. China Auranofin Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AGC Inc.
  • 18.6. Ardagh Group S.A.
  • 18.7. Corning Incorporated
  • 18.8. Guardian Industries
  • 18.9. Nippon Electric Glass Co. Ltd.
  • 18.10. Owens-Illinois Inc.
  • 18.11. Pilkington Group Limited
  • 18.12. PPG Industries Inc.
  • 18.13. Saint-Gobain S.A.
  • 18.14. Schott AG
  • 18.15. Vitro S.A.B. de C.V.

LIST OF FIGURES

  • FIGURE 1. GLOBAL AURANOFIN MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL AURANOFIN MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL AURANOFIN MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL AURANOFIN MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL AURANOFIN MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL AURANOFIN MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AURANOFIN MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL AURANOFIN MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES AURANOFIN MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA AURANOFIN MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL AURANOFIN MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL AURANOFIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL AURANOFIN MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL AURANOFIN MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL AURANOFIN MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL AURANOFIN MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL AURANOFIN MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL AURANOFIN MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL AURANOFIN MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL AURANOFIN MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL AURANOFIN MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL AURANOFIN MARKET SIZE, BY MODERATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL AURANOFIN MARKET SIZE, BY MODERATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL AURANOFIN MARKET SIZE, BY MODERATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL AURANOFIN MARKET SIZE, BY SEVERE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL AURANOFIN MARKET SIZE, BY SEVERE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL AURANOFIN MARKET SIZE, BY SEVERE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL AURANOFIN MARKET SIZE, BY DMARDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL AURANOFIN MARKET SIZE, BY DMARDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL AURANOFIN MARKET SIZE, BY DMARDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL AURANOFIN MARKET SIZE, BY DMARDS, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL AURANOFIN MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL AURANOFIN MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL AURANOFIN MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL AURANOFIN MARKET SIZE, BY CONVENTIONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL AURANOFIN MARKET SIZE, BY CONVENTIONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL AURANOFIN MARKET SIZE, BY CONVENTIONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL AURANOFIN MARKET SIZE, BY TARGETED SYNTHETIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL AURANOFIN MARKET SIZE, BY TARGETED SYNTHETIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL AURANOFIN MARKET SIZE, BY TARGETED SYNTHETIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL AURANOFIN MARKET SIZE, BY GOLD COMPOUNDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL AURANOFIN MARKET SIZE, BY GOLD COMPOUNDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL AURANOFIN MARKET SIZE, BY GOLD COMPOUNDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL AURANOFIN MARKET SIZE, BY 3MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL AURANOFIN MARKET SIZE, BY 3MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL AURANOFIN MARKET SIZE, BY 3MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL AURANOFIN MARKET SIZE, BY 6MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL AURANOFIN MARKET SIZE, BY 6MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL AURANOFIN MARKET SIZE, BY 6MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL AURANOFIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL AURANOFIN MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL AURANOFIN MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL AURANOFIN MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL AURANOFIN MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL AURANOFIN MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL AURANOFIN MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL AURANOFIN MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL AURANOFIN MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL AURANOFIN MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL AURANOFIN MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL AURANOFIN MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL AURANOFIN MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL AURANOFIN MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL AURANOFIN MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL AURANOFIN MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL AURANOFIN MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL AURANOFIN MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL AURANOFIN MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL AURANOFIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS AURANOFIN MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS AURANOFIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS AURANOFIN MARKET SIZE, BY DMARDS, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS AURANOFIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA AURANOFIN MARKET SIZE, BY DMARDS, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA AURANOFIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA AURANOFIN MARKET SIZE, BY DMARDS, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA AURANOFIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY DMARDS, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE AURANOFIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE AURANOFIN MARKET SIZE, BY DMARDS, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE AURANOFIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST AURANOFIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST AURANOFIN MARKET SIZE, BY DMARDS, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST AURANOFIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA AURANOFIN MARKET SIZE, BY DMARDS, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA AURANOFIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY DMARDS, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL AURANOFIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN AURANOFIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN AURANOFIN MARKET SIZE, BY DMARDS, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN AURANOFIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. GCC AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GCC AURANOFIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 152. GCC AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 153. GCC AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 154. GCC AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 155. GCC AURANOFIN MARKET SIZE, BY DMARDS, 2018-2032 (USD MILLION)
  • TABLE 156. GCC AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 157. GCC AURANOFIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. GCC AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION AURANOFIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION AURANOFIN MARKET SIZE, BY DMARDS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION AURANOFIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS AURANOFIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS AURANOFIN MARKET SIZE, BY DMARDS, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS AURANOFIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. G7 AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. G7 AURANOFIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 179. G7 AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 180. G7 AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 181. G7 AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 182. G7 AURANOFIN MARKET SIZE, BY DMARDS, 2018-2032 (USD MILLION)
  • TABLE 183. G7 AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 184. G7 AURANOFIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. G7 AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. NATO AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. NATO AURANOFIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 188. NATO AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 189. NATO AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 190. NATO AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 191. NATO AURANOFIN MARKET SIZE, BY DMARDS, 2018-2032 (USD MILLION)
  • TABLE 192. NATO AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 193. NATO AURANOFIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. NATO AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES AURANOFIN MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES AURANOFIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES AURANOFIN MARKET SIZE, BY DMARDS, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES AURANOFIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA AURANOFIN MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. CHINA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA AURANOFIN MARKET SIZE, BY DMARDS, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA AURANOFIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)